Elliot Stieglitz

Elliot Stieglitz

Auto-generated profile, based on publicly available information

Elliot Stieglitz

UCSF Benioff Children's Hospitals, San Francisco, California, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ESElliot Stieglitz
Elliot Stieglitz
ATAmaro N Taylor-Weiner
Amaro N Taylor-Weiner
TCTiffany Y Chang
Tiffany Y Chang
LGLaura C Gelston
Laura C Gelston
YWYong-Dong Wang
Yong-Dong Wang
MLMignon L Loh
Mignon L Loh
Elliot Stieglitz, Mignon Loh and colleagues report the whole-exome sequencing of diagnostic and relapsed samples from patients with juvenile myelomonocytic leukemia. They identify new recurrent mutations for this disease and find that the number of somatic alterations present at diagnosis may be predictive of clinical outcome. Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. Mutations in NF1, NRAS, KRAS, PTPN11 or CBL occur in 85% of patients, yet there are currently no risk stratification algorithms capable of predicting which patients will be refractory to conventional treatment and could therefore be candidates for experimental therapies. In addition, few molecular pathways aside from the RAS-MAPK pathway have been identified that could serve as the basis for such novel therapeutic strategies. We therefore sought to genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia to expand knowledge of the mutational spectrum in JMML. We identified recurrent mutations in genes involved in signal transduction, splicing, Polycomb repressive complex 2 (PRC2) and transcription. Notably, the number of somatic alterations present at diagnosis appears to be the major determinant of outcome.

26 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlyssa L. Kennedy
Alyssa L. Kennedy
KMKasiani C. Myers
Kasiani C. Myers
JBJames Bowman
James Bowman
CGChristopher J. Gibson
Christopher J. Gibson
NCNicholas D. Camarda
Nicholas D. Camarda
RLR. Coleman Lindsley
R. Coleman Lindsley
To understand the mechanisms that mediate germline genetic leukemia predisposition, we studied the inherited ribosomopathy Shwachman-Diamond syndrome (SDS), a bone marrow failure disorder with high risk of myeloid malignancies at an early age. To define the mechanistic basis of clonal hematopoiesis in SDS, we investigate somatic mutations acquired by patients with SDS followed longitudinally. Here we report that multiple independent somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of somatic clones via two distinct mechanisms with different clinical consequences. EIF6 inactivation mediates a compensatory pathway with limited leukemic potential by ameliorating the underlying SDS ribosome defect and enhancing clone fitness. TP53 mutations define a maladaptive pathway with enhanced leukemic potential by inactivating tumor suppressor checkpoints without correcting the ribosome defect. Subsequent development of leukemia was associated with acquisition of biallelic TP53 alterations. These results mechanistically link leukemia predisposition to germline genetic constraints on cellular fitness, and provide a rational framework for clinical surveillance strategies.

29 March 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
IIIlaria Iacobucci
Ilaria Iacobucci
JWJi Wen
Ji Wen
MMManja Meggendorfer
Manja Meggendorfer
JCJohn K. Choi
John K. Choi
LSLei Shi
Lei Shi
CMCharles G Mullighan
Charles G Mullighan

25 July 2013 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
ESElliot Stieglitz
Elliot Stieglitz
MLMignon L. Loh
Mignon L. Loh
While the majority of leukemia cases occur in the absence of any known predisposing factor, there are germline mutations that significantly increase the risk of developing hematopoietic malignancies in childhood. In this review article, we describe a number of these mutations and their clinical features. These predispositions can be broadly classified as those leading to bone marrow failure, those involving tumor suppressor genes, DNA repair defects, immunodeficiencies or other congenital syndromes associated with transient myeloid disorders. While leukemia can develop as a secondary event in the aforementioned syndromes, there are also several syndromes that specifically lead to the development of leukemia as their primary phenotype. Many of the genes discussed in this review can also be somatically mutated in other cancers, highlighting the importance of understanding shared alterations and mechanisms underpinning syndromic and sporadic leukemia.

27 July 2017 in Blood
Verified
Journal Article
Open access
PDF file
Akihide YoshimiAkihide Yoshimi
Akihide Yoshimi
MBMaria E. Balasis
Maria E. Balasis
AVAlexis Vedder
Alexis Vedder
KFKira Feldman
Kira Feldman
YMYan Ma
Yan Ma
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Key Points: Genetically accurate xenografts of CMML are achievable with near 100% frequency in NSGS mice. Robust human engraftment and overt phenotypes of CMML and JMML xenografts here facilitate preclinical therapeutic evaluation in vivo.

19 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ESElliot Stieglitz
Elliot Stieglitz
TMTali Mazor
Tali Mazor
AOAdam B. Olshen
Adam B. Olshen
HGHuimin Geng
Huimin Geng
LGLaura C. Gelston
Laura C. Gelston
MLMignon L. Loh
Mignon L. Loh
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder of childhood caused by mutations in the Ras pathway. Outcomes in JMML vary markedly from spontaneous resolution to rapid relapse after hematopoietic stem cell transplantation. Here, we hypothesized that DNA methylation patterns would help predict disease outcome and therefore performed genome-wide DNA methylation profiling in a cohort of 39 patients. Unsupervised hierarchical clustering identifies three clusters of patients. Importantly, these clusters differ significantly in terms of 4-year event-free survival, with the lowest methylation cluster having the highest rates of survival. These findings were validated in an independent cohort of 40 patients. Notably, all but one of 14 patients experiencing spontaneous resolution cluster together and closer to 22 healthy controls than to other JMML cases. Thus, we show that DNA methylation patterns in JMML are predictive of outcome and can identify the patients most likely to experience spontaneous resolution.